PKP2 and arrhythmogenic right ventricular cardiomyopathy: In vivo studies leveraging an adeno-associated viral (AAV) gene therapy strategy to drive cardiac expression of PKP2 (AAV-PKP2) at early and late disease stages in PKP2 Hom mice found that it was sufficient to restore PKP2 protein dose, scaffold the desmosome and prevent ARVC-related deficits, including prolonging lifespan.